Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Increasing potency and price of cannabis in Europe, 2006–16
Tom P. Freeman, Teodora Groshkova, Andrew Cunningham, et al.
Addiction (2018) Vol. 114, Iss. 6, pp. 1015-1023
Open Access | Times Cited: 117

Showing 1-25 of 117 citing articles:

New trends in cannabis potency in USA and Europe during the last decade (2008–2017)
Suman Chandra, Mohamed M. Radwan, Chandrani G. Majumdar, et al.
European Archives of Psychiatry and Clinical Neuroscience (2019) Vol. 269, Iss. 1, pp. 5-15
Closed Access | Times Cited: 405
Changes in delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta‐analysis
Tom P. Freeman, Sam Craft, Jack Wilson, et al.
Addiction (2020) Vol. 116, Iss. 5, pp. 1000-1010
Open Access | Times Cited: 253
How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review
Abigail M. Freeman, Kat Petrilli, Rachel Lees, et al.
Neuroscience & Biobehavioral Reviews (2019) Vol. 107, pp. 696-712
Open Access | Times Cited: 181
‘Standard THC units’: a proposal to standardize dose across all cannabis products and methods of administration
Tom P. Freeman, Valentina Lorenzetti
Addiction (2019) Vol. 115, Iss. 7, pp. 1207-1216
Open Access | Times Cited: 172
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
Tom P. Freeman, Chandni Hindocha, Gianluca Baio, et al.
The Lancet Psychiatry (2020) Vol. 7, Iss. 10, pp. 865-874
Open Access | Times Cited: 172
Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence
Lindsey A. Hines, Tom P. Freeman, Suzanne H. Gage, et al.
JAMA Psychiatry (2020) Vol. 77, Iss. 10, pp. 1044-1044
Open Access | Times Cited: 160
Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates
Jakob Manthey, Tom P. Freeman, Carolin Kilian, et al.
The Lancet Regional Health - Europe (2021) Vol. 10, pp. 100227-100227
Open Access | Times Cited: 126
Association between cannabis use disorder and schizophrenia stronger in young males than in females
Carsten Hjorthøj, Wilson M. Compton, Marie Starzer, et al.
Psychological Medicine (2023) Vol. 53, Iss. 15, pp. 7322-7328
Open Access | Times Cited: 44
Availability, retail price and potency of legal and illegal cannabis in Canada after recreational cannabis legalisation
Syed Mahamad, Elle Wadsworth, Vicki Rynard, et al.
Drug and Alcohol Review (2020) Vol. 39, Iss. 4, pp. 337-346
Closed Access | Times Cited: 121
Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review
Deborah S. Hasin, Claire Walsh
Journal of Clinical Medicine (2020) Vol. 10, Iss. 1, pp. 15-15
Open Access | Times Cited: 86
Use of alcohol, tobacco, cannabis, and other substances during the first wave of the SARS-CoV-2 pandemic in Europe: a survey on 36,000 European substance users
Jakob Manthey, Carolin Kilian, Sinclair Carr, et al.
Substance Abuse Treatment Prevention and Policy (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 82
Cannabis use in Europe: Current trends and public health concerns
Jakob Manthey
International Journal of Drug Policy (2019) Vol. 68, pp. 93-96
Closed Access | Times Cited: 81
Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study
Diego Quattrone, Laura Ferraro, Giada Tripoli, et al.
Psychological Medicine (2020) Vol. 51, Iss. 8, pp. 1329-1337
Open Access | Times Cited: 71
Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA
Vivian Chiu, Janni Leung, Wayne Hall, et al.
Neuropharmacology (2021) Vol. 193, pp. 108610-108610
Closed Access | Times Cited: 68
Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark
Carsten Hjorthøj, Christine Merrild Posselt, Merete Nordentoft
JAMA Psychiatry (2021) Vol. 78, Iss. 9, pp. 1013-1013
Open Access | Times Cited: 64
Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
Deepak Cyril D’Souza, Marta Di Forti, Suhas Ganesh, et al.
The World Journal of Biological Psychiatry (2022) Vol. 23, Iss. 10, pp. 719-742
Closed Access | Times Cited: 63
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders
Francisco Navarrete, María S. García‐Gutiérrez, Ani Gasparyan, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 59
Uncomfortably high: Testing reveals inflated THC potency on retail Cannabis labels
Anna L. Schwabe, Vanessa Johnson, Joshua Harrelson, et al.
PLoS ONE (2023) Vol. 18, Iss. 4, pp. e0282396-e0282396
Open Access | Times Cited: 24
Potency of Δ9–tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology
David J. Potter, K. M. Hammond, Shaun Tuffnell, et al.
Drug Testing and Analysis (2018) Vol. 10, Iss. 4, pp. 628-635
Open Access | Times Cited: 72
Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol
Samuel D. Banister, Jonathon C. Arnold, Mark Connor, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 5, pp. 2160-2175
Closed Access | Times Cited: 69
Does cannabis complement or substitute alcohol consumption? A systematic review of human and animal studies
Constanza Risso, Sadie Boniface, Meenakshi S. Subbaraman, et al.
Journal of Psychopharmacology (2020) Vol. 34, Iss. 9, pp. 938-954
Open Access | Times Cited: 65
Cannabis Legalization and Acute Harm From High Potency Cannabis Products: A Narrative Review and Recommendations for Public Health
Justin Matheson, Bernard Le Foll
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 58
The why behind the high: determinants of neurocognition during acute cannabis exposure
Johannes G. Ramaekers, Natasha L. Mason, Lilian Kloft, et al.
Nature reviews. Neuroscience (2021) Vol. 22, Iss. 7, pp. 439-454
Closed Access | Times Cited: 54
Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample
Sinikka L. Kvamme, Michael Mulbjerg Pedersen, Kristine Rømer Thomsen, et al.
Harm Reduction Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top